Keyword: Shionogi

A new study showing that the flu can become resistant to Roche's Xofluza may affect efforts to get the drug approved in the U.S. to treat children.

Novartis pivots Shanghai R&D from discovery to development. BeiGene nabs FDA nod for BTK inhibitor Brukinsa. FDA clears Shionogi's antibiotic Fetroja.

Shionogi's newest antibiotic Fetroja has now earned the FDA's approval, but will a mortality-rate warning scuttle the drug's chances?

FTC review delays Sandoz-Aurobindo generics deal. Manufacturing questions push back Zolgensma decision in Japan. AZ expects mid-teens China growth.

AZ and Daiichi's antibody-drug conjugate nabs FDA priority review; FDA shames Torrent for tainted heart drugs; Takeda sells emerging markets drugs.

The Novartis unit pivoting toward complex generics and biosims has licensed a newly approved branded med, Shionogi's constipation drug Symproic.

Gilead oncology EVP Riva joins Glenmark spinoff as CEO; Biocon's biosimilar plant dinged by FDA; Shionogi licenses Akili's digital therapeutics.

AZ's China sales jumped 25% in 2018; Pfizer Japan recalls valsartan drugs made with Mylan's API; resistance might hurt Shionogi and Roche's Xofluza.

Roche’s Xofluza has yet to see widespread uptake in the U.S., and new reports of resistance in Japan won’t help the drug’s case.

GlaxoSmithKline is rolling back its strict no-payments-to-doctors policy to allow some exceptions for select products and countries.